Cato Daily Podcast Would Wider Access to GLP-1s Throttle Addiction?
Jan 31, 2025
Nicholas Reville, Director of CASPR and an expert in addiction medicine, discusses the promising use of GLP-1 drugs like Ozempic in combating addiction. He argues for wider access to these medications, highlighting their potential to mitigate cravings linked to substance use disorders. The conversation touches on the off-label use of these drugs, the importance of ongoing research, and the role of compounding pharmacies in improving accessibility. Reville also calls for policy changes to encourage more pharmaceutical investment in addiction treatments, likening it to the impact of Narcan.
AI Snips
Chapters
Transcript
Episode notes
GLP-1s and Addiction
- GLP-1 drugs, effective for diabetes and weight loss, show promise in addiction treatment.
- They reduce cravings for food, alcohol, opioids, stimulants, and nicotine.
Off-Label Use
- Off-label drug use is legal; doctors can prescribe approved drugs for any purpose.
- Insurance, however, typically only covers on-label, FDA-approved uses.
Compounding GLP-1s
- Drug compounding allows other companies to manufacture drugs during shortages.
- Compounding pharmacies offer GLP-1s online at lower prices due to Ozempic and Mounjaro shortages.